BACKGROUND: The impact of donor-recipient ABO matching on outcomes after allogeneic stem cell transplantation has been a matter of controversy. STUDY DESIGN AND METHODS: Individual patient data-based meta-analysis was conducted with a pooled data set provided through six published and one unpublished cohorts. Outcomes in recipients of peripheral blood or bone marrow transplantation for hematologic malignancies were evaluated. A multivariate Cox model was used to adjust differences in outcomes of patients receiving ABO-matched grafts with those receiving major, minor, or bidirectional mismatched grafts. Considering multiple testing, p values of less than 0.05 and 0.001 were considered significant for the primary and secondary endpoints, respectively. RESULTS: In all, 1208 cases, including 697 ABO-matched and 202 major, 228 minor, and 81 bidirectional mismatched transplants, were analyzed. Overall, adverse impact of ABO matching on overall survival (OS), as a primary endpoint, was not observed (adjusted hazard ratios [95% confidence intervals]: major, 1.03 [0.82-1.30], p = 0.81; minor, 1.19 [0.97-1.47], p = 0.10; bidirectional, 1.25 [0.91-1.72], p = 0.17). Among related stem cell recipients, ABO matching had no significant influence on OS, while the minor and bidirectional mismatched groups among unrelated stem cell recipients exhibited lower OS with marginal significance, especially in patients with acute leukemia, patients who received transplants after 1998, and patients who underwent transplants at Asian centers. CONCLUSIONS: Our meta-analysis demonstrates no adverse association between any ABO mismatching and survival. However, marginally lower OS found in recipients of minor or bidirectional mismatched grafts from unrelated donors suggested the need for larger studies focusing on unrelated transplants.
BACKGROUND: The impact of donor-recipient ABO matching on outcomes after allogeneic stem cell transplantation has been a matter of controversy. STUDY DESIGN AND METHODS: Individual patient data-based meta-analysis was conducted with a pooled data set provided through six published and one unpublished cohorts. Outcomes in recipients of peripheral blood or bone marrow transplantation for hematologic malignancies were evaluated. A multivariate Cox model was used to adjust differences in outcomes of patients receiving ABO-matched grafts with those receiving major, minor, or bidirectional mismatched grafts. Considering multiple testing, p values of less than 0.05 and 0.001 were considered significant for the primary and secondary endpoints, respectively. RESULTS: In all, 1208 cases, including 697 ABO-matched and 202 major, 228 minor, and 81 bidirectional mismatched transplants, were analyzed. Overall, adverse impact of ABO matching on overall survival (OS), as a primary endpoint, was not observed (adjusted hazard ratios [95% confidence intervals]: major, 1.03 [0.82-1.30], p = 0.81; minor, 1.19 [0.97-1.47], p = 0.10; bidirectional, 1.25 [0.91-1.72], p = 0.17). Among related stem cell recipients, ABO matching had no significant influence on OS, while the minor and bidirectional mismatched groups among unrelated stem cell recipients exhibited lower OS with marginal significance, especially in patients with acute leukemia, patients who received transplants after 1998, and patients who underwent transplants at Asian centers. CONCLUSIONS: Our meta-analysis demonstrates no adverse association between any ABO mismatching and survival. However, marginally lower OS found in recipients of minor or bidirectional mismatched grafts from unrelated donors suggested the need for larger studies focusing on unrelated transplants.
Authors: Anita J Kumar; Soyoung Kim; Michael T Hemmer; Mukta Arora; Stephen R Spellman; Joseph A Pidala; Daniel R Couriel; Amin M Alousi; Mahmoud D Aljurf; Jean-Yves Cahn; Mitchell S Cairo; Corey S Cutler; Shatha Farhan; Usama Gergis; Gregory A Hale; Shahrukh K Hashmi; Yoshihiro Inamoto; Rammurti T Kamble; Mohamed A Kharfan-Dabaja; Margaret L MacMillan; David I Marks; Hideki Nakasone; Maxim Norkin; Muna Qayed; Olle Ringden; Harry C Schouten; Kirk R Schultz; Melhem M Solh; Takanori Teshima; Alvaro Urbano-Ispizua; Leo F Verdonck; Robert Peter Gale; Betty K Hamilton; Navneet S Majhail; Alison W Loren Journal: Blood Adv Date: 2018-05-08
Authors: Naynesh R Kamani; Mark C Walters; Shelly Carter; Victor Aquino; Joel A Brochstein; Sonali Chaudhury; Mary Eapen; Brian M Freed; Michael Grimley; John E Levine; Brent Logan; Theodore Moore; Julie Panepinto; Suhag Parikh; Michael A Pulsipher; Jane Sande; Kirk R Schultz; Stephen Spellman; Shalini Shenoy Journal: Biol Blood Marrow Transplant Date: 2012-02-16 Impact factor: 5.742
Authors: C K Brierley; T J Littlewood; A J Peniket; R Gregg; J Ward; A Clark; A Parker; R Malladi; P Medd Journal: Bone Marrow Transplant Date: 2015-04-13 Impact factor: 5.483
Authors: Lisa K Vande Vusse; David K Madtes; Katherine A Guthrie; Terry B Gernsheimer; J Randall Curtis; Timothy R Watkins Journal: Transfusion Date: 2013-08-27 Impact factor: 3.157